Search clinical trials for: IMM2510

Total 2 results

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Zhejiang Cancer Hospital; Fudan University

Recruiting

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shandong Cancer Hospital and Institute

Recruiting

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Squamous Cell Cancer of Head and Neck

China

3

Subscribe